Trial Profile
Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Patidegib (Primary)
- Indications Basal cell nevus syndrome
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors PellePharm
- 05 Jun 2018 Results (n=17) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2018 According to a PellePharm media release, data will be presented at the International Investigative Dermatology (IID) Meeting.
- 16 May 2018 Results presented in a PellePharm Media Release.